Passage Bio Inc PASG
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-02-28 |
| Shares Out. | 3,210,000 |
| Website | passagebio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 24 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$7.8M |
| Free Cash Flow | -$33.5M |
| Total Assets | $25.2M |
| Total Liabilities | $20.7M |
| Equity | $4.5M |
About Passage Bio Inc
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Passage Bio Inc is a publicly traded company under the ticker symbol PASG on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-09-01)